Literature DB >> 20599502

Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads.

Mouhamad Khoder1, Nicolas Tsapis, Valérie Domergue-Dupont, Claire Gueutin, Elias Fattal.   

Abstract

Residual antibiotics reaching the colon have many deleterious effects on the colonic microbiota including the selection of new antibiotic resistances. In order to avoid the selection of ciprofloxacin resistance, intestine or colon-targeted zinc-pectinate beads containing activated charcoal (AC) were designed for the inactivation of residual ciprofloxacin in the gastrointestinal tract of rats. Bead stability after oral administration was adjusted by tuning the concentration of zinc in the gelling bath and the number of washings. Intestine and colon-targeted beads were administered along with 50mg/kg of ciprofloxacin and ciprofloxacin was dosed in the plasma and the feces using HPLC. Ciprofloxacin pharmacokinetics was not affected by the oral co-administration of beads. The co-administration of intestine-targeted beads led to a significant decrease of the residual fecal free ciprofloxacin with a pronounced dose effect. Our study suggests the rat model is not appropriate for the investigation of bacteria responsive colon-targeted beads probably due to the important anatomical and physiological differences between human and rat gastrointestinal tracts. The ability of AC loaded zinc-pectinate beads to selectively decrease the intestinal residual fraction of ciprofloxacin could provide a better protection of the intestinal microbiota and may prevent the emergence of ciprofloxacin resistance in the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599502     DOI: 10.1016/j.ejps.2010.06.018

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  13 in total

1.  Correlation between fecal concentrations of ciprofloxacin and fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: toward new means to control the spread of resistance?

Authors:  Thu Thuy Nguyen; Elisabeth Chachaty; Clarisse Huy; Carole Cambier; Jean de Gunzburg; France Mentré; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

2.  Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.

Authors:  Charles Burdet; Sakina Sayah-Jeanne; Thu Thuy Nguyen; Christine Miossec; Nathalie Saint-Lu; Mark Pulse; William Weiss; Antoine Andremont; France Mentré; Jean de Gunzburg
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  TCDD administered on activated carbon eliminates bioavailability and subsequent shifts to a key murine gut commensal.

Authors:  Robert D Stedtfeld; J Brett Sallach; Robert B Crawford; Tiffany M Stedtfeld; Maggie R Williams; Hassan Waseem; Cliff T Johnston; Hui Li; Brian J Teppen; Norbert E Kaminski; Stephen A Boyd; James M Tiedje; Syed A Hashsham
Journal:  Appl Microbiol Biotechnol       Date:  2017-08-15       Impact factor: 4.813

4.  Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.

Authors:  Nathalie Grall; Laurent Massias; Thu Thuy Nguyen; Sakina Sayah-Jeanne; Nicolas Ducrot; Elisabeth Chachaty; Jean de Gunzburg; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

5.  Glucosylated nanoparticles for the oral delivery of antibiotics to the proximal small intestine protect mice from gut dysbiosis.

Authors:  Guorong Zhang; Qin Wang; Wanyin Tao; Wei Jiang; Eran Elinav; Yucai Wang; Shu Zhu
Journal:  Nat Biomed Eng       Date:  2022-07-07       Impact factor: 29.234

Review 6.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 7.  Perturbation of the human microbiome as a contributor to inflammatory bowel disease.

Authors:  Bayan Missaghi; Herman W Barkema; Karen L Madsen; Subrata Ghosh
Journal:  Pathogens       Date:  2014-06-30

8.  Protection of the Human Gut Microbiome From Antibiotics.

Authors:  Jean de Gunzburg; Amine Ghozlane; Annie Ducher; Emmanuelle Le Chatelier; Xavier Duval; Etienne Ruppé; Laurence Armand-Lefevre; Frédérique Sablier-Gallis; Charles Burdet; Loubna Alavoine; Elisabeth Chachaty; Violaine Augustin; Marina Varastet; Florence Levenez; Sean Kennedy; Nicolas Pons; France Mentré; Antoine Andremont
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

9.  Causes, consequences, and perspectives in the variations of intestinal density of colonization of multidrug-resistant enterobacteria.

Authors:  Etienne Ruppé; Antoine Andremont
Journal:  Front Microbiol       Date:  2013-05-28       Impact factor: 5.640

10.  Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted.

Authors:  Thu Thuy Nguyen; Jeremie Guedj; Elisabeth Chachaty; Jean de Gunzburg; Antoine Andremont; France Mentré
Journal:  PLoS Comput Biol       Date:  2014-09-11       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.